AboutTirzepatide,WhatdoYouNeedtoKnow?
-ByPhcokercom
Tirzepatidepeptide:
Sequence: YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
MolecularFor
mula: C225H348N48O68
MolecularWe
ight: 4813g/mol
PubChemCI
D: 156588324
CASNumber:2023788-19-2
Synonyms: LY3298176,Mounjaro,Zepbound,GTPL11429,P1206 Whatisobesity?/Howtotellifyouareobese?
Obesityisaseriousepidemicaffectinghealthworldwide.Factorssuchasgenet icsandenvironmentcancontributetoitsdevelopmentButthegoodnewsis,
PeptideGMPManufacturers www.phcoker.com
it'streatable.Sohowdowejudgewhetherweareobese?
Generally,healthcareproviderswilluseyourBMItodiagnoseobesityBMIisc alculatedbydividingweight(kg)byheight(m)squared[BMI=weight(kg)/hei ght2(m)]
Overweight:ABMIbetween25.0and29.9meansyouareoverweight.This isahealthissue.Beingoverweightputsastrainonyourbodyandcanle adtootherhealthproblems,suchasobesity.
Obesity:Obesitymeansthatyourweightisinanunhealthystate.YourBMI between30.0and39.9meansthatyouareobeseThisiswhenyouneed tocontactyourhealthcareproviderpromptlytounderstandandtreatobe sity.
Severeobesity:WhenyourBMIisgreaterthan40.0,youareinthestageof severeobesity,whichisverylikelytocauseyoutodevelopotherhealthproble ms.Whenyourealizeyouareseverelyobese,youneedtotalktoyourhealth careprovideraboutmanagementoptions
WhatisTirzepatidePowder?
Tirzepatideisaweightlossdruginjectedonceaweekforweightmanagement. Thedrug,developedbyEliLillyandCompany,iscurrentlyapprovedbytheF DAtotreattype2diabetes.Tirzepatideiscurrentlysoldunderthetradenames MounjaroandZepbound.AsaprofessionalTirzepatidesupplier,Phcoker.comc annotonlyprovidehigh-qualityTirzepatidelyophilizedpowderinvials,butals orawpowder.
AsadualreceptoragonistofGLP-1andGIP,Tirzepatidenotonlystimulatesin sulinsecretionandrelease,butalsohasacertaininhibitoryeffectonglucagon. ThroughthedualeffectsofGLP-1andGIP,Tirzepatidecaneffectivelysuppres sappetite,reducefoodintake,andprolongthefeelingofsatiety,therebypro motingweightloss
ThedualeffectsofTirzepatidecannotonlyeffectivelyreduceweight,butthis innovativemethodmakesfulluseoftheadvantagesofthesetwohormonesto solvemanyproblemssuchasmetabolism,andalsomakesitaneffectivetreat mentfortype2diabetes.apromisingtreatmentoption.
WhyTirzepatideissoPopular?/BenefitsofTirzepatide
Asabiologicalpeptidedrug,Tirzepatideispopularinthemarketbecauseoft hebenefitsitbringstopeople.Itisawell-knowndrugfortreatingdiabetesan daneffectiveweightlossdrug.
Promoteweightloss.StudieshaveshownthatTirzepatideactivateshuman GIPandGLP-1receptorsGIPandGLP-1receptorsaretworeceptorscruci altoregulatingappetiteinthehumanbrainTirzepatidehasbeenshownt oreducefoodintake,suppressappetiteandregulatefatutilization.Numero usclinicalstudieshaveshownthatpatientstakingtezeparatidelost15.7% (34.4poundsor15.6kilograms)ofbodyweight,makingitapotentialoptio nforthoseseekingeffectiveweightmanagement.
Increasessatiety.Tirzepatideslowsthepassageoffoodthroughthebody, reducesthedesiretoeat,andenhancesthebody'sfeelingoffullness,maki ngiteasiertosticktoahealthydietandmaintainweightloss.
Controlandstabilizebloodsugarlevels.Type2diabetesisachronicpro gressivediseaseandthemostcommonformofdiabetes.Thisdiseasecaus esthebody'sowninabilitytoreleaseinsulin,resultinginhighlevelsofglu coseinthebloodTirzepatidecanregulatethereleaseanduseofinsulinb yregulatingGLP-1andGIP,therebykeepingglycatedhemoglobin(HbA1c) atahealthylevel.
Treattype2diabetes.TirzepatidepeptidehasbeenapprovedbytheFDA forthetreatmentoftype2diabetesandcaneffectivelyhelppatientscontr olbloodsugar.Regulatesbloodsugarlevelsmainlybyincreasingthesecret ionofinsulin.
Treatobesity-relateddiseases.Obesitycanleadtophysicaldiseasessuch ashighbloodpressure,hyperglycemia,hyperlipidemia,andevenheartdisea se.Tirzepatidecaneffectivelyreducetheoccurrenceanddevelopmentofth esediseaseswhileprotectingthecardiovascularsystembypromotingweigh tloss.
ConvenientUnlikeotherdrugsthatmustbetakeneveryday,Tirzepatideo nlyneedstobeinjectedonceaweek,whichgreatlyhelpspatientssaveal otoftimeintheirdailylivesandmakestakingthedrugmoreconvenient.
Flexibledosing.Tirzepatidecanbeadministeredflexibly.Itcanbeusedalon eorincombinationwithotherdiabetesmedications.Thisflexibledosingm ethodallowspatientstomodifythedosageaccordingtotheirneeds,there byachievingbettertherapeuticeffects.
Inaddition,researcherscontinuetostudythepotentialbenefitsofTirzepatide powder.PotentialbenefitsofTirzepatideareasfollows:
Protectheart
Reduceinflammation
Treatalcoholaddiction
ThesestudiesareongoingtoexploreTirzpatide'sbroaderbenefitsbeyondobes ityandtype2diabetes.ThepowerfuleffectsshownbyTizepatidepeptidehav emadeitwidelypopularinthemarket.IfyouareinterestedinTizepatidepo wder,makesuretopurchaseitfromareliablepeptidemanufacturersuchasP hcoker.com.
TirzepatideVsSemaglutide
TirzepatideandSemaglutidearetwodrugscurrentlyonthemarketforweight managementandtreatmentoftype2diabetes.Itisbecomingmoreandmore commontousedrugstoloseweight,sowhatarethesimilaritiesanddifferenc esbetweenthesetwocommondrugs?
TirzepatideandSemaglutidebothbelongtotheGLP-1seriesofweightlossdr
ugsandhaveahugeeffectonweightlossandthetreatmentandmanagemen toftype2diabetes.Andthesideeffectscausedbyusingthesetwodrugsare generallythesameThemainsideeffectisadverseintestinalreactions
IsTirzepatidebetterthanSemaglutide?
Semaglutideisaglucagon-likepeptide(GLP-1)receptoragonist.Wheneating,i tpromotesthereleaseofGLP-1hormoneandproducesinsulin.Atthesameti me,itcanalsosendsatietysignalstothebrain,therebyreducingfoodintake andachievingweightloss.
Tirzepatideisanagonistoftworeceptors:glucagon-likepeptide(GLP-1)andgl ucose-dependentinsulinotropicpolypeptide(GIP),whichmeansthatTirzepatide mayalsoprovideadditionaleffectsonweightlossandachievebetterresults Theamountofweightlosseffect.
Cantheyallpromoteweightloss?
Asthestudycontinued,researchersfoundthatTirzepatideledtogreaterweigh tlossthanSemaglutide.Studieshaveshownsignificantweightlosswithweekly dosesof5mg,10mgand15mgofTirzepatide.AlthoughTirzepatideismor eexpensivethanSemaglutide,itismoreeffectiveandbettervalue
Ofnote,thedosesofTirzepatideandSemaglutideusedinthesestudieswere different.ThedosageofTirzepatideintheseexperimentswashigher,whichma yhavehadacertainimpactontheresultsoftheexperiments.Inaddition,the sestudiesonlycomparedpatientswithtype2diabetes,andtheeffectsofwei ghtlossonobesepatientswithouttype2diabeteshavenotbeenclearlycom pared.
ReferencedCitations:
[1]"Australianprescriptionmedicinedecisionsummaries:Mounjaro"TherapeuticGoodsAdministration Archivedfromtheoriginalon5February2023Retrieved28February2023
[2]"Mounjarotirzepatide15mg/05mLsolutionforinjectionpre-filledpen(379334)"TherapeuticGoods Administration.Archivedfromtheoriginalon3January2023.Retrieved28February2023.
[3]"PublicSummary:Mounjarotirzepatide15mg/05mLsolutionforinjectionpre-filledpen"Therapeutic GoodsAdministrationRetrieved28February2023
[4]"Notice:MultipleAdditionstothePrescriptionDrugList(PDL)[2023-03-08]".HealthCanada.8March 2023Archivedfromtheoriginalon22March2023Retrieved21March2023
[5]"SummaryBasisofDecision-Mounjaro"HealthCanada17March2023Archivedfromtheoriginal on25April2023Retrieved24April2023
[6]ThomasMK,NikooienejadA,BrayR,CuiX,WilsonJ,DuffinK,etal(January2021)"DualGIPand GLP-1ReceptorAgonistTirzepatideImprovesBeta-cellFunctionandInsulinSensitivityinType2 Diabetes"TheJournalofClinicalEndocrinologyandMetabolism106(2):388–396 doi:101210/clinem/dgaa863PMC7823251PMID33236115
[7]"FDAApprovesNovel,Dual-TargetedTreatmentforType2Diabetes"USFoodandDrug Administration(FDA)(Pressrelease)13May2022Archivedfromtheoriginalon13May2022 Retrieved13May2022PublicDomainThisarticleincorporatestextfromthissource,whichisinthe publicdomain